Abcam, ab277866, Human RICTOR knockout A549 cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
RICTOR KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 43 bp deletion in exon 5. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 43 bp deletion in exon 5,
Disease:Carcinoma

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-RICTOR, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Zygosity-Homozygous, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
RICTOR (Rapamycin-insensitive companion of mTOR) is an important component of the mTOR complex 2 (mTORC2) distinguished by its ability to interact with mTOR (mechanistic target of rapamycin). RICTOR possesses a molecular mass of approximately 192 kDa. You can find RICTOR widely expressed in various tissues including the brain liver and skeletal muscle. Researchers also refer to it as AVO3.
Biological function summary
The protein plays a significant role in cellular growth proliferation and survival. RICTOR forms part of the mTORC2 complex which is important for Akt/PKB phosphorylation. Activation of mTORC2 by RICTOR regulates actin cytoskeleton dynamics and membrane trafficking. This involvement affects the control of cell metabolism and immune responses.
Pathways
RICTOR integrates into the PI3K/Akt signaling pathway influencing cell growth and survival in response to nutrients and growth factors. RICTOR as part of mTORC2 also interacts with proteins such as Sin1 and mLST8 helping regulate PKB/Akt phosphorylation at Ser473. This interaction links RICTOR's function to the insulin signaling pathway which controls aspects of glucose metabolism.
The dysregulation of RICTOR plays a role in cancer progression and metabolic disorders. Alterations in the PI3K/Akt/mTOR signaling pathway can lead to the development of various cancers with RICTOR contributing to tumorigenesis through Akt activation. Additionally aberrant RICTOR expression affects insulin signaling therefore connecting it to diabetes. Through these pathways and conditions RICTOR's interaction with proteins such as mTOR illustrates its relevance in disease mechanisms and therapeutic targets.